• The medical director of Veritas Int., Dr. Luis Izquierdo López, one of the most recognized geneticists in our country, participated with the presentation “The 10 most important advances in genetics applied to gynecology”.
• In the presentation he talked about the new forms of diagnosis based on genomic information that, applied to the field of gynecology, are changing the approach of both oncological gynecology and other problems related to the area of ​​women’s health.

Veritas Intercontinental, a subsidiary of Veritas Genetics, a global leader in Genome sequencing and interpretation, showed the potential of Patient-Oriented Diagnosis in the Genomic Era at the VIII GINEP Scientific Meeting, which was held on October 25 and 26 in Granada. Veritas Int. was also one of the sponsors of this scientific event that brought together the main specialists in different fields of gynecology.

The medical director of Veritas Int., Dr. Luis Izquierdo López participated with a presentation in which he presented The 10 most important advances in genetics applied to gynecology based on the sequencing of Genome and Complete Exome.

During the congress, the Veritas commercial team was explaining the use of our genetic tests myCancerRiskDNA, myNewbornDNA and myGenome applied to the field of women’s health and prevention in general.

Genomic medicine

Genomic medicine is based on the use of the genetic information of an individual to achieve the best approach oriented to preventive health care or in case of presenting symptoms, achieve a diagnosis or determine the appropriate treatment. Genetic information helps to estimate the risk of certain diseases in order to prevent or detect them early, also allowing to choose the most appropriate drug for each individual, at the precise dose.

There are new forms of diagnosis, based on genomic information, that allow improving the overall care of women, both within the scope of gynecology and in other aspects of her life. With genomic information it is possible to adapt the medical management of women to detect early and treat different diseases that can affect her such as hereditary cancer, the risk of thrombi, vitamin deficiency or the risk of Alzheimer’s among others.

4P Medicine

Genomic medicine is the basis of 4P medicine. It is preventive because it allows to detect people at risk of suffering a disease and offers tools to avoid it. It is Predictive because genetic studies detect the risk of suffering a disease in the future. It is personalized because it puts the focus on the individual, treating the patient and not just a pathology in a generalized way. And it is Participatory because the patient collaborates in making decisions about their health.

A tool for life

Genome sequencing and interpretation is a key preventive tool, useful for a lifetime, providing information about variants that can cause common diseases such as cardiovascular disease and cancer, diseases that can be transmitted to children, pharmacogenomic information to adapt the prescription of drugs, multifactorial diseases and much more.

It is estimated that 1 in 3 people will develop cancer throughout their lives, between 5 and 10% are hereditary. Knowing the variants related to this type of cancer allows acting in time to reduce this risk or detect it early.

Cardiovascular diseases are the leading cause of hospitalization and many of them have an important hereditary component. About 50% of the population is a carrier of recessive diseases and knowing the status of the carrier is essential for those who are planning to start a family. Genetics is also present in certain disorders of coagulation, endocrine, metabolic, in the health of the organs, in mitochondrial diseases and neurological disorders.

The Genome offers a complete map of our organism: it analyzes in depth the risk of hereditary cancer and risk of cardiovascular pathology, also including information about neurological alterations, organ health, coagulation disorders, endocrine and metabolic diseases, immunological disorders, information pharmacogenomics as well as the analysis of diseases of which we can be a carrier and therefore we can transmit to our children.

Genomic Medical Centers

Veritas Int. In collaboration with different clinics and hospitals is creating Genomic Medicine Units, with a double orientation, a preventive aspect, aimed at a healthy population, and another diagnosis, in which to meet the demands of a patient with suspected hereditary disease . In both cases, pursuing the same objective: to facilitate the population’s access to genomic medicine.

About Veritas Intercontinental

Veritas Intercontinental is the international subsidiary of Veritas Genetics, The Genome Company, which operates in Europe, Latin America, Japan and the Emirates. Its mission is to boost the entire genome and offer people information that empowers them to maximize the quality and duration of their lives and their families, changing the way the world conceives genetics.

Veritas was the first company to offer sequencing and interpretation of the complete genome to consumers and their doctors and leads the field of genetics, expanding the limits of science and technology and reducing the cost of the genome.

Veritas was founded in 2014 by leaders in genomics from Harvard Medical School and operates worldwide from its offices in the United States, Europe and China. The company has been recognized MIT Technology Review as one of the 50 Smartest Companies in 2016 and 2017, by Fast Company as one of the most innovative health companies in the world in 2018, and by CNBC as one of the Disruptor 50 companies in 2018 and 2019.